XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.3

Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Astellas Agreement [Member] | Japan [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total Consideration	$ 117,394
Astellas Agreement [Member] | Japan [Member] | Development Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total Consideration	17,047
Astellas Agreement [Member] | Japan [Member] | License Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total Consideration	100,347
Astellas Agreement [Member] | Europe [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total Consideration	904,897
Astellas Agreement [Member] | Europe [Member] | Development Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total Consideration	285,922
Astellas Agreement [Member] | Europe [Member] | License Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total Consideration	618,975
AstraZeneca Agreements [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Deferred Revenue	177,576	$ 175,646
AstraZeneca Agreements [Member] | U.S./RoW and China [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	1,143,193
Deferred Revenue	177,576
Total Consideration	1,320,769
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | License Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	344,493
Deferred Revenue	0
Total Consideration	344,493
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | Co-development, information sharing & committee services [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	623,619
Deferred Revenue	0
Total Consideration	623,619
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | China performance obligation [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	175,081
Deferred Revenue	177,576
Total Consideration	$ 352,657

X

- Definition

The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.

+ References

No definition available.

+ Details

Name:	fgen_CashConsiderationReceivedUnderCollaborationAgreement
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date.

+ References

No definition available.

+ Details

Name:	fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479837/606-10-45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=fgen_ChinaPerformanceObligationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: